Report Description Table of Contents Postoperative Pain Management Market: How Are Outpatient Surgery and Non-Opioid Options Changing Recovery Care? – (Updated On: 10th-Nov-2026) According to Strategic Market Research, the Global Postoperative Pain Management Market was valued at USD 26.74 billion in 2025 and is projected to reach USD 43.43 billion by 2032, growing at a CAGR of 7.2% during 2026–2032. Substantial surgical activity and continued need for pain relief following hospital and outpatient procedures support market demand. According to the U.S. Agency for Healthcare Research and Quality (AHRQ), approximately 13.5 million qualifying ambulatory surgery encounters occurred in U.S. hospital-owned facilities in 2023, an increase of 9% from 12.4 million in 2022. Globally, the 2025 Lancet Commission on Global Surgery identified an unmet need for at least 160 million additional operations annually, highlighting the substantial potential demand for surgical care and associated postoperative pain treatment. Acute Postoperative Pain and Treatment Demand: A U.S. national survey involving 300 surgical patients found that approximately 86% experienced postoperative pain, with 75% of those patients reporting moderate to extreme pain. The same study found that 74% of patients experiencing postoperative pain reported moderate to extreme pain after discharge. These findings highlight demand for effective analgesics during hospitalization and recovery at home. Multimodal Pain Management: Clinical practice increasingly emphasizes combining non-opioid medications, regional anesthesia and carefully selected opioid treatments. The American Pain Society's postoperative pain management guideline recommends multimodal pain management for appropriate surgical patients. Acetaminophen, NSAIDs, local anesthetics and regional nerve blocks remain important treatment options, supporting demand across several established analgesic categories. Non-Opioid Drug Innovation: In January 2025, the U.S. FDA approved Vertex Pharmaceuticals' Journavx (suzetrigine) for moderate-to-severe acute pain in adults. The FDA's clinical evaluation involved 2,447 patients across three trials, including studies following abdominal and foot surgery. This approval expands the availability of non-opioid options for postoperative pain management. Extended-Duration Local Anesthetics: Products such as Pacira BioSciences' Exparel and Heron Therapeutics' Zynrelef provide additional options for pain relief following selected surgical procedures. The U.S. Centers for Medicare & Medicaid Services provides additional payments for qualifying non-opioid pain treatments in applicable outpatient hospital and ambulatory surgical settings, supporting commercial opportunities for eligible products. Pipeline Development: In November 2026, Adneuris Therapeutics submitted an FDA New Drug Application for cebranopadol, supported by Phase 3 clinical studies involving acute surgical pain. The development highlights continued pharmaceutical investment in differentiated treatments for moderate-to-severe pain. Market Outlook: The Postoperative Pain Management Market is supported by surgical recovery needs and continued development of non-opioid analgesics. Extended-duration local anesthetics, new oral treatments and reimbursement support offer opportunities for pharmaceutical manufacturers, while clinical effectiveness and safety will remain important factors influencing market adoption through 2032. Which Segments Are Leading and Expanding Fastest in the Postoperative Pain Management Market? By Drug Class: Opioids Remain in Severe Pain Care as Local Anesthetics Gain Ground Leading Segment: Opioid Analgesics Opioid analgesics accounted for the largest 36% share of the Postoperative Pain Management Market, valued at approximately USD 9.626 billion in 2025, and are projected to grow at a CAGR of 5.20% during 2026–2032. Opioid analgesics play a significant role in managing moderate-to-severe acute postoperative pain, particularly following major orthopedic, abdominal, and cardiovascular surgeries. Their established use in hospital-based pain management, especially when non-opioid medications provide insufficient relief, supports their continued importance in postoperative care and recovery. Fastest-Growing Segment: Local Anesthetics Local anesthetics accounted for 23% of the Global Postoperative Pain Management Market, valued at USD 6.150 billion in 2025, and are projected to register the fastest CAGR of 9.40% during 2026–2032. Their growing importance in multimodal postoperative pain management reflects the increasing preference for targeted pain relief and reduced reliance on systemic opioid medications. Wider adoption of local anesthetics in surgical recovery, regional anesthesia, and postoperative pain control is supporting their expanding role in improving patient comfort and recovery outcomes. By Route of Administration: Oral Analgesics Carry Pain Relief From Hospital to Home Leading and Fastest-Growing Segment: Oral Administration Oral administration dominated the Postoperative Pain Management Market, accounting for the largest 46% market share, equivalent to approximately USD 12.300 billion in 2025, and is projected to expand at the fastest CAGR of 7.80% during 2026–2032. Oral medications remain central to multimodal analgesia (MMA), supporting effective postoperative pain relief, improving patient comfort, and reducing dependence on intravenous treatments and high-risk opioids. Their widespread use during hospital recovery and continued pain management after discharge further strengthens their market position. By Treatment Type: Multimodal Regimens Broaden Pain Relief Options and Reduce Opioid Exposure Leading Segment: Pharmacological Pain Management Pharmacological pain management accounted for the largest 48% share of the Postoperative Pain Management Market, reaching approximately USD 12.835 billion in 2025, with an anticipated CAGR of 5.90% during 2026–2032. Medications remain central to postoperative recovery by relieving surgical pain, reducing physiological stress, and supporting early patient mobilization and rehabilitation. The widespread use of analgesics, including opioids, nonsteroidal anti-inflammatory drugs, and local anesthetics, across surgical care settings reinforces the importance of pharmacological approaches in improving patient comfort and postoperative recovery outcomes. Fastest-Growing Segment: Multimodal Pain Management Multimodal pain management accounted for a 29% share, valued at USD 7.755 billion in 2025, and is projected to expand at the fastest CAGR of 8.79% during 2026–2032. Multimodal analgesia combines different classes of pain-relieving medications, regional or neuraxial anesthesia, and non-pharmacological therapies to improve postoperative pain control. Its growing adoption across surgical procedures reflects increasing clinical preference for comprehensive pain relief, reduced opioid exposure, improved patient recovery, and shorter hospital stays. By Surgery Type: Joint Replacements and Spine Procedures Drive Orthopedic Analgesia Leading and Fastest-Growing Segment: Orthopedic Surgery Orthopedic surgery held the largest share of the Postoperative Pain Management Market at 40%, accounting for approximately USD 10.696 billion in 2025, and is projected to register the fastest CAGR of 8.20% during 2026–2032. High postoperative pain intensity following joint replacements, spinal procedures, and fracture surgeries is accelerating the adoption of multimodal analgesia (MMA). Combining targeted, low-dose medications with non-pharmacological pain management approaches supports effective postoperative recovery, reduces opioid exposure, and strengthens the role of orthopedic procedures in advancing postoperative pain management practices. By End User: Hospitals Handle the Largest Caseload as Outpatient Centers Expand Same-Day Care Leading Segment: Hospitals Hospitals dominated the Postoperative Pain Management Market, accounting for the largest 70% market share, valued at USD 18.718 billion in 2025, and are projected to grow at a CAGR of 6.60% during 2026–2032. Their leading position reflects the high volume of surgical procedures requiring effective pain management, multidisciplinary clinical care, and continuous patient monitoring. Hospitals follow structured postoperative pain management protocols, combining medication, specialist supervision, and round-the-clock assessment to improve pain control, minimize complications, accelerate recovery, and support better surgical outcomes. Fastest-Growing Segment: Ambulatory Surgical Centers Ambulatory surgical centers (ASCs) accounted for 20% of the Postoperative Pain Management Market, contributing approximately USD 5.348 billion in 2025, and are projected to grow at the fastest CAGR of 9.40% during 2026–2032. Growth is supported by increasing outpatient surgical procedures and greater emphasis on effective pain control, faster recovery, and same-day discharge. ASCs are increasingly adopting multimodal analgesia and opioid-sparing pain management approaches to improve postoperative comfort, reduce opioid exposure, and support safe recovery at home following surgical procedures. By Geography: Opioid-Sparing Care Advances in North America as Surgical Access Expands in Asia-Pacific Leading Region: North America North America dominated the Postoperative Pain Management Market with a 39% share, valued at approximately USD 10.429 billion in 2025, and is projected to grow at a CAGR of 6.60% during 2026–2032. The region's leadership is supported by the widespread adoption of multimodal analgesia and structured postoperative recovery pathways, reducing reliance on traditional opioid-based pain relief. Increasing use of non-opioid medications, regional anesthesia, and enhanced recovery protocols across hospitals and surgical centers continues to strengthen postoperative pain management practices throughout North America. Fastest-Growing Region: Asia-Pacific Asia-Pacific accounted for 25% of the global Postoperative Pain Management Market, valued at approximately USD 6.685 billion in 2025, and is projected to record the fastest regional CAGR of 8.72% during 2026–2032. Growth is supported by increasing surgical procedures, expanding hospital infrastructure, and greater adoption of advanced postoperative pain management practices across China, India, Japan, and South Korea. Rising investments in surgical care facilities, improved access to pain management therapies, and growing emphasis on effective postoperative recovery are strengthening regional market expansion. Which FDA-Approved Drugs Are Shaping Postoperative Pain Management? Journavx (Suzetrigine) – Vertex Pharmaceuticals: Approved by the FDA in January 2025 for moderate-to-severe acute pain in adults, Journavx introduced a new non-opioid treatment option. Its approval represents an important commercial development in postoperative pain management, particularly for patients requiring alternatives to opioid analgesics. Exparel (Liposomal Bupivacaine) – Pacira BioSciences: FDA-approved for postsurgical local analgesia through infiltration and specified regional nerve blocks. Exparel is an important branded treatment in extended-duration postoperative pain control, particularly in orthopedic and other surgical procedures. Zynrelef (Bupivacaine and Meloxicam) – Heron Therapeutics: FDA-approved for postsurgical analgesia in adults following specified surgical procedures. The extended-release combination supports localized pain management and represents an additional branded option within opioid-sparing postoperative care. Caldolor (Intravenous Ibuprofen) – Cumberland Pharmaceuticals: FDA-approved for pain management in adults and pediatric patients aged 3 months and older. Its intravenous formulation supports postoperative analgesia when oral medication administration is unsuitable. Ofirmev (Intravenous Acetaminophen) – Originally Developed by Cadence Pharmaceuticals: FDA-approved intravenous acetaminophen provides an established non-opioid treatment option for acute pain management. It is relevant to hospital-based multimodal analgesia and postoperative recovery. Toradol (Ketorolac Tromethamine) – Multiple Manufacturers of Generic Formulations: Ketorolac is an FDA-approved NSAID used for short-term management of moderately severe acute pain requiring analgesia at the opioid level, including postoperative pain. Its injectable and oral formulations retain clinical relevance in short-duration postoperative treatment. Morphine, Oxycodone, Hydromorphone, and Fentanyl – Multiple Pharmaceutical Manufacturers: These FDA-approved opioid analgesics remain important for managing severe postoperative pain when clinically appropriate. Their use is influenced by opioid stewardship, patient monitoring, and increasing availability of non-opioid treatment alternatives. Which Companies Are Leading the Postoperative Pain Management Market? Pacira BioSciences – Leading Position in Extended-Release Local Anesthetics Pacira BioSciences is a prominent company in postoperative pain management through Exparel (liposomal bupivacaine), initially approved by the FDA in 2011. The company has expanded Exparel's approved applications to include selected regional nerve blocks, supporting its position in opioid-sparing postoperative analgesia. Exparel is used in surgical settings including orthopedic procedures, where longer-lasting localized pain relief can support recovery. Pacira's commercial opportunities are closely linked to the expanding adoption of regional anesthesia and multimodal analgesia. Heron Therapeutics – Established Innovator in Non-Opioid Postsurgical Analgesia Heron Therapeutics has strengthened its position through Zynrelef (bupivacaine and meloxicam), which received initial FDA approval in May 2021. The product combines two non-opioid medications in an extended-release formulation for postoperative pain management. Subsequent regulatory expansions have broadened its applications across specified surgical procedures. Heron's focus on localized analgesia positions the company within the growing market for opioid-sparing postoperative treatments, particularly in hospital and outpatient surgical settings. Vertex Pharmaceuticals – Emerging Leader in Novel Non-Opioid Pain Treatment Vertex Pharmaceuticals entered the acute pain treatment market with Journavx (suzetrigine), approved by the FDA on January 30, 2025, for moderate-to-severe acute pain in adults. The FDA reported that its clinical development program included 2,447 patients across three trials, including studies involving abdominoplasty and bunionectomy procedures. Journavx represents an important pharmaceutical innovation because it introduces an additional oral non-opioid option for acute postoperative pain. Its commercial potential is associated with wider adoption of non-opioid analgesia. Other Key Companies and Their Market Roles: Pfizer: Supplies established analgesic medicines, including opioid and non-opioid products, supporting postoperative pain treatment across healthcare settings. Fresenius Kabi: Provides injectable analgesics, anesthetics, and related hospital medications used in surgical and postoperative care. Baxter International: Supports postoperative pain management through hospital medication delivery, infusion technologies, and related acute-care products. Johnson & Johnson: Participates in the broader surgical care ecosystem through surgical technologies and medical products supporting operative and postoperative care. Analyst Commentary: Where Can Longer-Lasting Non-Opioid Therapies Stand Out? The postoperative pain management market presents significant opportunities for companies developing longer-lasting non-opioid analgesics and targeted pain therapies. FDA-approved innovations such as Journavx, Exparel, and Zynrelef are creating opportunities for product differentiation. Manufacturers demonstrating sustained pain relief, reduced opioid requirements, and improved postoperative recovery outcomes are well-positioned to strengthen their competitive presence. Postoperative Pain Management Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 26.74 Billion Revenue Forecast in 2032 USD 43.43 Billion Overall Growth Rate CAGR of 7.2% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Drug Class, By Route of Administration, By Treatment Type, By Surgery Type, By End User, By Geography By Drug Class Opioid Analgesics, Nonsteroidal Anti-Inflammatory Drugs, Local Anesthetics, Other Non-Opioid and Adjuvant Analgesics By Route of Administration Oral Administration, Intravenous Administration, Epidural Administration By Treatment Type Pharmacological Pain Management, Regional Anesthesia and Nerve Blocks, Multimodal Pain Management By Surgery Type Orthopedic Surgery, General Surgery, Cardiovascular Surgery By End User Hospitals, Ambulatory Surgical Centers, Specialty Surgical Clinics By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Rising ambulatory surgery volumes, continued need for pain relief after discharge, wider use of multimodal pain management, and expanded access to non-opioid analgesics and longer-acting local anesthetics Customization Option Available upon request Frequently Asked Question About This Report Q1. What factors are driving growth across the market? A1. Growth is supported by high surgical volumes, substantial postoperative pain burden, increasing outpatient procedures, and wider adoption of multimodal and opioid-sparing pain management. Q2. What treatment trends are reshaping the industry? A2. The industry is shifting toward multimodal analgesia, regional nerve blocks, extended-duration local anesthetics, and newer non-opioid medicines designed to reduce reliance on conventional opioids. Q3. Why are local anesthetics gaining importance in the market? A3. Local anesthetics are projected to record the fastest drug-class CAGR of 9.40% during 2026–2032. Greater use of regional anesthesia and extended-release formulations is supporting their adoption. Q4. Which treatment approach offers the strongest growth opportunity in the industry? A4. Multimodal pain management is projected to expand at the fastest treatment-type CAGR of 8.79% during 2026–2032. Combining different analgesic approaches can improve pain control while reducing opioid exposure. Q5. Which surgery type contributes the most to the market? A5. Orthopedic surgery accounts for the largest share at 40% in 2025 and is also projected to grow fastest at 8.20% during 2026–2032, supported by joint replacements, spinal procedures, and rehabilitation needs. Q6. How are outpatient procedures influencing the industry? A6. Ambulatory surgical centers are projected to record the fastest end-user CAGR of 9.40% during 2026–2032. Increasing same-day surgery is strengthening demand for longer-lasting and opioid-sparing pain treatments that support recovery at home. Q7. Which region is expected to expand the fastest in the market? A7. Asia-Pacific is projected to record the fastest regional CAGR of 8.72% during 2026–2032. Growth is supported by expanding surgical capacity, hospital infrastructure, and access to advanced postoperative pain therapies across major regional markets. Sources: AHRQ — U.S. hospital-owned facilities recorded 13.5 million qualifying ambulatory surgery encounters in 2023. AHRQ — Nationwide Ambulatory Surgery Sample · MedPAC — 2026 Report on Ambulatory Surgical Center Services The Lancet — At least 160 million additional operations are needed worldwide each year. The Lancet — Surgical Health Policy 2025–35 Postoperative pain studies — 86% of 300 participants in a historical U.S. survey reported pain after surgery. PubMed — U.S. National Postsurgical Pain Survey · PubMed — 2025 Ambulatory Surgery Pain Cohort American Pain Society, ASRA, and ASA — Joint clinical guidance supports multimodal postoperative pain management. Journal of Pain — Clinical Practice Guideline on Postoperative Pain AAOS — The 2026 joint replacement registry report recorded 35,495 ambulatory surgical center submissions for 2025. AAOS — 2026 American Joint Replacement Registry Findings U.S. FDA and Vertex — Journavx was approved on January 30, 2025, for moderate-to-severe acute pain in adults. FDA — Journavx Approval · FDA — Journavx Trial Snapshot · Vertex — Q3 2026 Financial Results CMS — Medicare provides temporary separate payments for qualifying non-opioid pain treatments in hospital outpatient departments and ASCs through December 31, 2027. CMS — Qualifying Non-Opioid Treatments and Billing Codes Pacira and Viatris — Exparel generated USD 142.5 million in Q3 2026 net product sales. FDA labeling covers local infiltration and specified nerve blocks. FDA — Exparel Prescribing Information · Pacira — Q3 2026 Form 10-Q · Pacira and Viatris — Acquisition Agreement Heron and CorMedix — Zynrelef generated USD 10.6 million in Q3 2026 net revenue, up 13.8% year over year. FDA labeling documents pain reduction for up to 72 hours in specified studies. FDA — Zynrelef Prescribing Information · SEC — Heron Q3 2026 Financial Results · Heron and CorMedix — Asset Purchase Agreement Adneuris Therapeutics — The company announced its cebranopadol New Drug Application submission on November 9, 2026. Adneuris — November 2026 NDA Submission Announcement · ClinicalTrials.gov — ALLEVIATE-1 · ClinicalTrials.gov — ALLEVIATE-2 FDA, Cumberland, and DailyMed — Direct sources for Caldolor, Ofirmev, and ketorolac. FDA — Caldolor Supplemental Approval · DailyMed — Ofirmev Label · DailyMed — Ketorolac Label Pfizer, Fresenius Kabi, Baxter, and J&J — Product sources clarify the companies’ different roles. Pfizer — Ketorolac Injection · Fresenius Kabi — IV Acetaminophen · FDA — Baxter Novum IQ Infusion Pump · J&J MedTech — Surgical Wound Closure Portfolio Haisco — China approved HSK21542 for mild-to-moderate pain after abdominal surgery in May 2025. Haisco — Regulatory Filing on HSK21542 · Nature Communications — HSK21542 Phase III Postoperative Pain Trials Table of Contents - Global Postoperative Pain Management Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Drug Class, Route of Administration, Treatment Type, Surgery Type, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Drug Class, Route of Administration, Treatment Type, Surgery Type, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Drug Class, Route of Administration, Treatment Type, Surgery Type, and End User Investment Opportunities in the Postoperative Pain Management Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Non-Opioid Analgesics, Extended-Duration Local Anesthetics, Multimodal Pain Management, Regional Anesthesia, and Outpatient Surgical Recovery Emerging Opportunities in Novel Acute Pain Treatments and Opioid-Sparing Therapies Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Postoperative Pain Management in Surgical Recovery, Outpatient Care, and Opioid-Sparing Treatment Role of Multimodal Analgesia and Extended-Duration Local Anesthetics in Recovery Care Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory and Public Health Factors Role of Multimodal Pain Management, Non-Opioid Analgesics, and Regional Anesthesia in Market Expansion Impact of Outpatient Surgery, Same-Day Discharge, and Postoperative Recovery at Home Opioid Stewardship, Clinical Effectiveness, Treatment Safety, and Reimbursement Trends Impact of FDA Approvals and Pipeline Development on Postoperative Pain Treatment Global Postoperative Pain Management Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class: Opioid Analgesics Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Local Anesthetics Other Non-Opioid and Adjuvant Analgesics Market Analysis by Route of Administration: Oral Administration Intravenous Administration Epidural Administration Market Analysis by Treatment Type: Pharmacological Pain Management Regional Anesthesia and Nerve Blocks Multimodal Pain Management Market Analysis by Surgery Type: Orthopedic Surgery General Surgery Cardiovascular Surgery Market Analysis by End User: Hospitals Ambulatory Surgical Centers Specialty Surgical Clinics Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Postoperative Pain Management Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class, Route of Administration, Treatment Type, Surgery Type, and End User Country-Level Breakdown: United States Canada Mexico Europe Postoperative Pain Management Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class, Route of Administration, Treatment Type, Surgery Type, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific Postoperative Pain Management Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class, Route of Administration, Treatment Type, Surgery Type, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Postoperative Pain Management Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class, Route of Administration, Treatment Type, Surgery Type, and End User Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Postoperative Pain Management Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class, Route of Administration, Treatment Type, Surgery Type, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Pacira BioSciences, Inc. Heron Therapeutics, Inc. Vertex Pharmaceuticals Incorporated Cumberland Pharmaceuticals Inc. Pfizer Inc. Fresenius Kabi AG Baxter International Inc. Johnson & Johnson Adneuris Therapeutics Hikma Pharmaceuticals PLC Teva Pharmaceutical Industries Ltd. Viatris Inc. Competitive Landscape and Strategic Insights Benchmarking Based on Analgesic Portfolios, Clinical Effectiveness, Safety Profiles, Product Availability, and Regional Presence Supplier Qualification and Regulatory Compliance Capability Analysis Non-Opioid Analgesic Portfolio Positioning Extended-Duration Local Anesthetic Product Positioning Opioid and Opioid-Sparing Treatment Strategy Analysis Regional Anesthesia, Nerve Block, and Multimodal Pain Management Capabilities Pipeline Development and Regulatory Milestones (2025–2032) Appendix Abbreviations and Terminologies Used in the Report References and Sources Historical Data Coverage (2019–2024) Base Year Definitions and Assumptions (2025) Forecast Methodology and Assumptions (2026–2032) List of Tables Market Size by Drug Class, Route of Administration, Treatment Type, Surgery Type, End User, and Region (2026–2032) Historical Market Size and Volume (2019–2024), Base Year Market Size Analysis (2025), and Forecast (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Country-Level Market Analysis Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Competitive Benchmarking of Leading Vendors Regulatory Approvals, Reimbursement, and Non-Opioid Treatment Analysis Product and Pipeline Overview: Journavx, Exparel, Zynrelef, Caldolor, and Ofirmev Technology and Treatment Adoption Across Pharmacological Pain Management, Regional Anesthesia, Nerve Blocks, and Multimodal Pain Management List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Drug Class, Route of Administration, Treatment Type, Surgery Type, and End User (2025 vs. 2032) Global Postoperative Pain Management Ecosystem and Value Chain Analysis Non-Opioid Analgesic Innovation and Extended-Duration Local Anesthetic Trends (2025–2032)